Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
209lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Learning paths
Pick a track — progress rings update as you complete lessons.
25 lessons
9mPeptidesIntermediate
MOTS-C in July 2026: The FDA Review, Human Data, and What to Track
MOTS-C sits at the intersection of mitochondrial signaling, metabolism, and longevity. July 2026 put it back in the spotlight for a reason.
9mPeptidesIntermediate
Injectable Peptides in Sports Medicine: What the Evidence and Antidoping Rules Actually Say
Sports medicine keeps pulling peptides into the conversation because recovery pressure is real. The hard part is separating promising biology from weak evidence, gray-market hype, and antidoping risk.
9mPeptidesIntermediate
Retatrutide Is Approaching Surgery-Level Weight Loss: What the New Data Actually Means
Retatrutide's weight-loss signal is now strong enough that people are comparing it with surgery. That comparison is useful, but only if you understand what the numbers do and do not mean.
9mPeptidesIntermediate
Semax: The Neuroprotective Peptide Changing Cognitive Research
Semax is an ACTH-derived peptide that upregulates BDNF and supports neuroprotection. Here's what the research actually shows — and how to track your cognitive protocol.
9mPeptidesIntermediate
Retatrutide Cuts Knee Pain by 75.8%: What the TRIUMPH-4 Trial Means Beyond Weight Loss
Everyone focused on the 71-pound weight loss stat from TRIUMPH-4. But the buried finding — 75.8% reduction in knee pain scores — may be the more important number for anyone living with joint pain.
8mPeptidesIntermediate
BRP Peptide: Stanford's AI-Discovered 'Natural Ozempic' Explained
A Stanford AI tool screened 2,600 uncharacterized peptides and identified BRP — a 12-amino acid molecule that cuts food intake by up to 50%, promotes fat burning, and avoids the nausea, constipation, and muscle loss common with GLP-1 drugs. Here's what the research actually shows.
9mPeptidesIntermediate
Tesamorelin: The Science-Backed Growth Hormone Peptide for Fat Loss and Longevity
Tesamorelin is an FDA-approved GHRH analog with clinical trials proving 15–20% visceral fat reduction. Here's the full science, dosing guide, and what the latest research reveals about its longevity applications.
10mPeptidesIntermediate
GHK-Cu Regulates Over 4,000 Human Genes: The Epigenetic Science Explained
Most people know GHK-Cu for skin and wound healing. What they don't know: it's one of the most potent epigenetic regulators ever studied, influencing over 4,000 human genes — many tied directly to aging, inflammation, and tissue repair.
9mPeptidesIntermediate
MOTS-c Enters Phase 2a Human Trial for Prediabetes: What the Research Shows
MOTS-c — a peptide synthesized inside your own mitochondria — is now in Phase 2a human trials for prediabetes. Early data suggests it improves insulin sensitivity and metabolic flexibility without the side effects of pharmaceutical interventions.
10mPeptidesIntermediate
Retatrutide Phase 3 Results: 28.7% Body Weight Reduction Sets a New Standard
Phase 3 trial data is in: retatrutide delivers 28.7% average body weight reduction, outpacing every approved GLP-1 therapy. The numbers tell a clear story about where metabolic medicine is heading.
9mPeptidesIntermediate
GHK-Cu: The Copper Peptide Accelerating Wound Healing and Skin Regeneration
A 2026 Phase 2 clinical trial confirms GHK-Cu achieves 25% faster wound closure and tissue regeneration versus control. Discover how this naturally occurring copper peptide triggers stem cell activity, collagen synthesis, and anti-inflammatory cascades.
10mPeptidesIntermediate
36 Studies Confirm BPC-157 Heals Musculoskeletal Tissue: What the New Systematic Review Found
The largest systematic review of BPC-157 to date analyzed 36 studies and confirmed consistent healing outcomes across tendons, ligaments, bone, and muscle tissue. Here's what the data shows.
11mPeptidesIntermediate
Why Retatrutide is Winning: Clinical Data Shows 28% Superior Fat Loss Over GLP-1
A 2026 meta-analysis comparing retatrutide to GLP-1 (Ozempic/Wegovy) and tirzepatide shows retatrutide delivers 28% superior fat loss. Here's the science behind why the triple-agonist approach is reshaping weight loss and body recomposition.
10mPeptidesIntermediate
TB-500 and Cardiac Recovery: What the 2026 Human Trial Data Shows
TB-500 has moved from rodent models to human cardiac recovery trials. The 2026 data is early, but the mechanism and results are worth understanding — especially if you're using TB-500 for recovery.
11mPeptidesIntermediate
BPC-157: The Peptide That Regenerates Tissue—Science, Clinical Evidence, and Real Results
BPC-157 activates multiple tissue repair pathways simultaneously. Users report faster recovery from injury, improved gut healing, enhanced joint mobility—backed by published clinical data.
10mPeptidesIntermediate
The Science of Retatrutide: How GLP-1/GIP/Glucagon Triple Agonists Work
Retatrutide's triple receptor mechanism simultaneously suppresses appetite, enhances metabolic function, and activates thermogenesis. Here's the science behind why it delivers 24% body weight reduction.
14mPeptidesAdvanced
Peptides for Longevity: The Emerging Science Behind Age-Reversal Compounds
The peptide space is shifting from weight loss toward longevity. Explore the science behind peptides designed to slow aging, repair cellular damage, and extend healthspan.
10mPeptidesIntermediate
Latest Peptide Research Breakthroughs: What's Coming in 2026
The peptide space is evolving rapidly. Here's what researchers are discovering, which new compounds show promise, and what breakthroughs could hit the market soon.
10mPeptidesIntermediate
How Retatrutide Works: The Science Behind the Triple-Receptor Agonist
Retatrutide is not just a stronger tirzepatide. It's a fundamentally different molecule with three receptor targets instead of two. Here's how each mechanism contributes to rapid fat loss, metabolic optimization, and muscle preservation.
10mPeptidesIntermediate
Why Retatrutide Preserves Muscle Better Than Tirzepatide
Rapid fat loss typically means muscle loss. But retatrutide's triple action—including glucagon receptor activation—preserves more lean mass than tirzepatide or GLP-1-only compounds. Here's the science.
12mPeptidesIntermediate
Retatrutide vs Tirzepatide: What the Latest Clinical Data Shows
Retatrutide and tirzepatide dominate the peptide conversation, but they're not interchangeable. Here's what the latest clinical research reveals about their differences, efficacy, and mechanisms.
10mPeptidesIntermediate
BPC-157: The Peptide That Heals Joints, Ligaments, and Muscle Faster
BPC-157 is showing remarkable promise in clinical research for rapid tissue regeneration. Learn how this pentapeptide works, what the data shows, and whether it's right for your recovery protocol.
8mPeptidesIntermediate
Retatrutide Phase 3 Results: What the Clinical Data Tells Us
New Phase 3 data shows retatrutide delivering superior metabolic benefits. Here's what researchers found and why it matters.
10mPeptidesIntermediate
Retatrutide Shows 23% Superior Weight Loss vs Tirzepatide in Phase 3 Trial
Retatrutide, the triple-action GLP-1/GIP/glucagon receptor agonist, outperforms tirzepatide by 23% in the latest human clinical trial—the most comprehensive weight loss comparison to date.
10mPeptidesIntermediate
Retatrutide: The Triple-Action Weight Loss Peptide Explained
Retatrutide is a next-generation weight loss peptide targeting three metabolic pathways. Here's how it works and why it outperforms earlier GLP-1 therapies.
Also available at /blog for legacy links.